Twitxy Saved

Seven Seven Six

Verified account This account is verified. Learn more

@sevensevensix

Founded by builders, built by founders; earliest investors in building the future we want for our kids. IRL @776NYC
Worldwide sevensevensix.com/portfolio Joined September 2020
776 Following 44K Followers 10K Posts

Latest posts 5

Seven Seven Six Verified account @sevensevensix
Only one person on that panel is building a replacement part for the human eye 👁️ Go get 'em, Nicole!!

x.com/LambdaVision/s…
LambdaVision, Inc. @LambdaVision 1d
Today our CEO @NicoleWagnerPhD joins the @IntrepidMuseum Unstoppable Women event in NYC.

We’re proud to celebrate women-led innovation while keeping our work focused on advancing our artificial retina.

#WomenInBiotech
View quoted post on X
Seven Seven Six Verified account @sevensevensix
All that talking about it was the spec. A trainer knows exactly where scheduling breaks for trainers, and that niche was always too small for a software company to chase. Now the person with the problem ships the fix.

x.com/GergelyOrosz/s…
Gergely Orosz Verified account @GergelyOrosz 2d
Hot damn I’m seeing first-hand how AI makes non-developers build production software:

The personal trainer at my gym has been talking for 3+ years about building a scheduling + workout app one day. Nontechnical.

He now has his app!! GitHub + Cloudflare BE&DB + Resend. All built with Claude

They guy spent 3 months on it, and has not slept as much as before since getting hooked on building software with AI
View quoted post on X
Seven Seven Six Verified account @sevensevensix
Problem is people switch insurance all the time. The plan paying for the drug in year one often isn't the plan still holding the member when the savings show up.

x.com/ZReitano/statu…
Z Reitano Verified account @ZReitano 4d
CVS just put a number on the GLP-1 break-even question. Using Aetna claims, they estimate that at ~$350/month, medical savings roughly offset the drug cost over 3 years.

Compared with matched non-users, GLP-1 users had:
- 10-12% fewer ER visits in years 1 and 2
- 14% lower odds of a major cardiovascular event
- 34-42% fewer hospitalizations among those still on the drug at year 3

At today’s employer prices (~$617-766/mo), plans saved $9,400 per person on medical but spent $13,300 more on Rx. Net: +$3,900.

The interesting part: cash prices (~$299-349) and Medicare’s $245 pilot price are already below CVS’s break-even. The barrier isn’t what these drugs can be sold for. It’s what employers are paying.

Family coverage now costs $28,303 a year (KFF). That’s why employers are dropping GLP-1s, not because the drugs don’t work. At ~$350/mo, they wouldn’t have to choose.

A few call outs: it's a CVS white paper... (insert disclaimers). Observational. Diabetes and obesity pooled. The year-3 group (n≈4,000) is people who stayed on, who may differ from those who stopped. And CVS has a seat at this negotiating table.

Affordability drives access.
View quoted post on X